<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01911520</url>
  </required_header>
  <id_info>
    <org_study_id>2010/207</org_study_id>
    <secondary_id>2009-016857-16</secondary_id>
    <nct_id>NCT01911520</nct_id>
  </id_info>
  <brief_title>Dose Finding Study for Effective Reversal of a Deep Rocuronium-induced Neuromuscular Block With Sugammadex in Morbidly Obese Patients</brief_title>
  <acronym>BRIDION</acronym>
  <official_title>Dose Finding Study for Effective Reversal of a Deep Rocuronium-induced Neuromuscular Block With Sugammadex in Morbidly Obese Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Ghent</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Ghent</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      During laparoscopic bariatric surgery, adequate muscle relaxation is important to maintain
      good surgical conditions. To achieve this muscle relaxation, neuromuscular transmission
      blocking agents, such as rocuronium (Esmeron速) are used. It sometimes happens that there is
      still some neuromuscular blocking activity left in the patient on awakening from anesthesia.
      This is called residual curarization and is known to cause postoperative complications such
      as impairment of respiratory function.

      Sugammadex (Bridion速) is a novel drug which selectively binds rocuronium (Esmeron速). It
      allows for reversing of neuromuscular transmission blocking activity. Until now, all studies
      with sugammadex were performed in non-obese patients.

      Obese patient have a high risk to suffer from post-operative respiratory failure. Therefore
      it is vital to avoid residual curarization. Sugammadex might be an important factor.

      Obese patients have a large total body weight different from ideal body weight. Recent
      research demonstrated that the dose for the neuromuscular blocking agent rocuronium
      (Esmeron速) needs to be calculated on the patients' Ideal Body Weight rather than on Total
      Body Weight.

      At this moment no data is available on the dose-response relationship of sugammadex in
      morbidly obese patients.

      We hypothesize that in morbidly obese patients sugammadex should be dosed on ideal
      bodyweight, instead of total bodyweight.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Flowchart :

      72 participants

      Stratification

      BMI&lt;50 BMI &gt;50

      Randomization Randomization

      TBW IBW TBW IBW

      2mg/kg n=9 2mg/kg n=9 2mg/kg n=9 2mg/kg n=9 4mg/kg n=9 4mg/kg n=9 4mg/kg n=9 4mg/kg n=9

      TBW : Total Body Weight IBW : Ideal Body Weight
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to complete recovery of muscle relaxation, 30 minutes after end of surgery.</measure>
    <time_frame>30 minutes after end of surgery.</time_frame>
    <description>Measured with TOF Watch SX (TOF ratio &gt; 0.9); clinical evaluation (eg head lift) of residual curarization in the Post Anesthetic Care.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to complete recovery of muscle relaxation, 1 hour after the end of surgery.</measure>
    <time_frame>1hour after end of surgery.</time_frame>
    <description>Measured with TOF Watch SX (TOF ratio &gt; 0.9); clinical evaluation (eg head lift) of residual curarization in the Post Anesthetic Care.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to complete recovery of muscle relaxation, 1 hour 30 minutes after the end of surgery.</measure>
    <time_frame>1hour 30 minutes after end of surgery.</time_frame>
    <description>Measured with TOF Watch SX (TOF ratio &gt; 0.9); clinical evaluation (eg head lift) of residual curarization in the Post Anesthetic Care.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to complete recovery of muscle relaxation, 2 hours after the end of surgery.</measure>
    <time_frame>2 hours after end of surgery.</time_frame>
    <description>Measured with TOF Watch SX (TOF ratio &gt; 0.9); clinical evaluation (eg head lift) of residual curarization in the Post Anesthetic Care.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Need/use of rescue medication at the end of surgery</measure>
    <time_frame>The hours following the end of surgery.</time_frame>
    <description>Additional administration of sugammadex 2 mg/kg Total Body Weight) at the end of surgery.</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Morbidly Obese Patients.</condition>
  <arm_group>
    <arm_group_label>BMI &lt; 50, Total Body Weight (TBW), 2mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with a BMI &lt; 50, who will be dosed according to total body weight.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BMI &lt; 50, TBW, 4 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with a BMI &lt; 50, who will be dosed according to total body weight.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BMI &lt; 50, Ideal Body Weight (IBW), 2 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with a BMI &lt; 50, who will be dosed according to ideal body weight.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BMI &lt; 50, IBW, 4 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with a BMI &lt; 50, who will be dosed according to ideal body weight.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BMI &gt; 50, TBW, 2mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with a BMI &gt; 50, who will be dosed according to total body weight.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BMI &gt; 50, TBW, 4mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with a BMI &gt; 50, who will be dosed according to total body weight.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BMI &gt;50, IBW, 2 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with a BMI &gt; 50, who will be dosed according to ideal body weight.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BMI &gt;50, IBW, 4 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with a BMI &gt; 50, who will be dosed according to ideal body weight.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugammadex 2 mg/kg</intervention_name>
    <description>Patients receive 2 mg/kg Sugammadex.</description>
    <arm_group_label>BMI &lt; 50, Total Body Weight (TBW), 2mg/kg</arm_group_label>
    <arm_group_label>BMI &lt; 50, Ideal Body Weight (IBW), 2 mg/kg</arm_group_label>
    <arm_group_label>BMI &gt; 50, TBW, 2mg/kg</arm_group_label>
    <arm_group_label>BMI &gt;50, IBW, 2 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugammadex. 4 mg/kg</intervention_name>
    <description>Patients receive 4 mg/kg Sugammadex.</description>
    <arm_group_label>BMI &lt; 50, TBW, 4 mg/kg</arm_group_label>
    <arm_group_label>BMI &lt; 50, IBW, 4 mg/kg</arm_group_label>
    <arm_group_label>BMI &gt; 50, TBW, 4mg/kg</arm_group_label>
    <arm_group_label>BMI &gt;50, IBW, 4 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Neuromuscular monitoring.</intervention_name>
    <description>Neuromuscular monitoring using a TOF watch SX (Organon).</description>
    <arm_group_label>BMI &lt; 50, Total Body Weight (TBW), 2mg/kg</arm_group_label>
    <arm_group_label>BMI &lt; 50, TBW, 4 mg/kg</arm_group_label>
    <arm_group_label>BMI &lt; 50, Ideal Body Weight (IBW), 2 mg/kg</arm_group_label>
    <arm_group_label>BMI &lt; 50, IBW, 4 mg/kg</arm_group_label>
    <arm_group_label>BMI &gt; 50, TBW, 2mg/kg</arm_group_label>
    <arm_group_label>BMI &gt; 50, TBW, 4mg/kg</arm_group_label>
    <arm_group_label>BMI &gt;50, IBW, 2 mg/kg</arm_group_label>
    <arm_group_label>BMI &gt;50, IBW, 4 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Clinical evaluation of residual curarization .</intervention_name>
    <description>Every 30 min, during the first 2 hours after the end of the surgery.</description>
    <arm_group_label>BMI &lt; 50, Total Body Weight (TBW), 2mg/kg</arm_group_label>
    <arm_group_label>BMI &lt; 50, TBW, 4 mg/kg</arm_group_label>
    <arm_group_label>BMI &lt; 50, Ideal Body Weight (IBW), 2 mg/kg</arm_group_label>
    <arm_group_label>BMI &lt; 50, IBW, 4 mg/kg</arm_group_label>
    <arm_group_label>BMI &gt; 50, TBW, 2mg/kg</arm_group_label>
    <arm_group_label>BMI &gt; 50, TBW, 4mg/kg</arm_group_label>
    <arm_group_label>BMI &gt;50, IBW, 2 mg/kg</arm_group_label>
    <arm_group_label>BMI &gt;50, IBW, 4 mg/kg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria :

          -  ASA I-II-III

          -  Age 18 - 65 year

          -  Male or female

          -  BMI &gt; 30

        Exclusion criteria :

          -  Renal failure

          -  Liver dysfunction

          -  Breastfeeding female patients, or female patients without reliable contraception

          -  Neuromuscular disease

          -  Malignant hyperthermia or a family history of malignant hyperthermia

          -  Allergy for neuromuscular blocking agents or other medications used during general
             anesthesia

          -  Infectious disease or patients with fever

          -  Patients who already received rocuronium or sugammadex on the day of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jurgen Van Limmen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Ghent</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Luc De Baerdemaeker, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Ghent</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Koen Reyntjens, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Ghent</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ghent University Hospital</name>
      <address>
        <city>Ghent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>http://www.uzgent.be</url>
  </link>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 23, 2013</study_first_submitted>
  <study_first_submitted_qc>July 26, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2013</study_first_posted>
  <last_update_submitted>July 26, 2013</last_update_submitted>
  <last_update_submitted_qc>July 26, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rocuronium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

